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Background: HIV-1 infection or systemic lupus erythematosus (SLE) disrupt B cell
homeostasis, reduce memory B cells, and impair function of IgG and IgM antibodies.
Objective: To determine how disturbances in B cell populations producing polyclonal anti-
bodies relate to the IgM repertoire, the IgM transcriptome in health and disease was
explored at the complementarity determining region 3 (CDRH3) sequence level.
Methods: 454-deep pyrosequencing in combination with a novel analysis pipeline was
applied to define populations of IGHM CDRH3 sequences based on absence or presence
of somatic hypermutations (SHM) in peripheral blood B cells.
Results: HIV or SLE subjects have reduced biodiversity within their IGHM transcriptome
compared to healthy subjects, mainly due to a significant decrease in the number of unique
combinations of alleles, although recombination machinery was intact. While major differ-
ences between sequences without or with SHM occurred among all groups, IGHD and
IGHJ allele use, CDRH3 length distribution, or generation of SHM were similar among study
cohorts. Antiretroviral therapy failed to normalize IGHM biodiversity in HIV-infected individ-
uals. All subjects had a low frequency of allelic combinations within the IGHM repertoire
similar to known broadly neutralizing HIV-1 antibodies.
Conclusion: Polyclonal expansion would decrease overall IgM biodiversity independent of
other mechanisms for development of the B cell repertoire. Applying deep sequencing as
a strategy to follow development of the IgM repertoire in health and disease provides a
novel molecular assessment of multiple points along the B cell differentiation pathway that
is highly sensitive for detecting perturbations within the repertoire at the population level.
Keywords: IgM antibody transcriptome repertoire, biodiversity, HIV-1, systemic lupus erythematosus, somatic
hypermutation, naïve B cells, IgM memory B cells, pyrosequencing
INTRODUCTION
HIV-1 infection and systemic lupus erythematosus (SLE) each
results in defective B cell activation and differentiation (1, 2). Both
conditions have decreased proportions of CD27+ class switched
memory B cells, increased B cell apoptosis, and increased expres-
sion of B cell activation markers (3–6). In HIV infection, disrup-
tion of B cell homeostasis and loss of normal B cell architecture
within lymphoid tissues occur early in disease and persist even
with control of viral replication following antiretroviral therapy
(ART) (7, 8). Individuals with SLE display defects in B cell check-
points in both early and late stage development contributing to
impaired tolerance and autoantibody production (9).
The dynamics between defects in B cell function and under-
lying molecular perturbations in the B cell repertoire during the
course of infection or autoimmunity have not been extensively
evaluated, reflecting in part the challenge of generating sufficiently
robust data sets by conventional clonal sequencing. Massively par-
allel deep sequencing has revolutionized the capacity to evaluate
the depth and breadth of the immunoglobulin (Ig) repertoire
(10). Application of deep sequencing to probe the Ig heavy chain
variable region (IGH) repertoire along the B cell developmental
pathway may pin point HIV-mediated defects over the antibody
maturation, and uncover evidence for elusive broadly neutraliz-
ing HIV-specific antibodies (bn-HIV-Ab) critical to development
of an effective HIV vaccine. This study focused on IGHM reper-
toire at early B cell developmental stage before isotype switch.
IgM is the initial antibody generated when encountering anti-
gen. Activated IgM B cells confer substantial response in acute
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HIV-infection (11–13). IgM antibodies demonstrated broad spec-
trum and high affinity to HIV-1 envelope glycoproteins, neutral-
ized HIV-1 more potently than IgG due to pentameric binding
nature, and prevented viral entry across the mucous membrane
(14, 15).
The limited repertoire of bn-HIV-Ab share biochemical, struc-
tural, and functional features resembling natural polyreactive
autoantibodies and are produced by individuals with autoimmu-
nity, particularly SLE, and a significant proportion of HIV-infected
individuals (16–25). Polyreactive autoantibodies and bn-HIV-Ab
are frequently IgG (26–28), or can be IgA (29–32). More than a
third of SLE individuals have IgM antibodies reactive with HIV-1
gp41-derived peptides (33), a CD4-reactive IgM Fab clone iso-
lated from a healthy individual inhibited HIV-1 replication (34),
and IgM autoantibodies blocked HIV-1 entry (35).
While polyreactive antibodies are well-characterized at the bio-
chemical level, molecular assessment of the Ig repertoire among
populations of B cells that produce polyreactive antibodies is lim-
ited. Our current in-depth analysis based on deep sequencing
of the IgM transcriptome was designed to examine the mole-
cular repertoire of IGH complementarity determining region 3
(CDRH3) in IgM among individuals with SLE or HIV-1 infection
and relate the findings to a group of healthy individuals by analy-
sis of biodiversity. Biodiversity is used in population genetics to
present a unified view of variation of life forms within habitats
based on the premise that genomes are taxonomically similar, ran-
domly distributed, and sufficiently large (36, 37). Assessments of
biodiversity from deep sequencing data provide unprecedented
views of the richness of immune loci in primates, zebra fish,
and humans (38–41). The goal for our study was to determine
how disturbances in B cell populations producing polyclonal anti-
bodies relate to biodiversity of the IgM repertoire by examining
key components, including allele usage, V-D-J recombination and
junctional diversity, and extent of somatic hypermutation (SHM),
which collectively contribute to differences in Ig biodiversity
between health and disease.
MATERIALS AND METHODS
STUDY COHORT
Sixteen individuals, enrolled in a protocol approved by the Insti-
tutional Review Boards of the University of Florida and the
University of South Florida, included four groups (n= 4 per
group): healthy controls (HC), subjects with SLE, and HIV-1
infected individuals either therapy-naïve (HIV) or receiving com-
bination antiretroviral therapy (cART) (HIVTx) (Table 1). Groups
within the cohort were age-balanced with median (25–75% quar-
tile range) age of 20 (16–22) years. SLE subjects were untreated
and diagnosed by clinical and laboratory criteria defined by the
American College of Rheumatology (42). Therapy-naïve subjects
were HIV-1 infected by sexual transmission for at least 6 months
(Table 1). HIVTx individuals were infected either through mater-
nal to child transmission or by contaminated blood products
for 16.0 (12.3–21.3) years, treated for 8.0 (1.5–17.5) years, and
achieved viral suppression (log10 HIV-1 RNA copies/ml< 1.7),
and CD4> 25% for 1.9 (0.5–6.0) years at the time of study
(Table 1). No subject received any vaccination 30 days prior to
study entry, and/or had acute infection to reduce the chance of
plasma cell circulating in peripheral blood. Informed consent was
obtained from all subjects.
B CELL PROFILES BY MULTIPARAMETER FLOW CYTOMETRY
Immunofluorescence staining was performed using the whole
blood lysis method (43) and analysis by LSR2 flow cytometer (BD
Biosciences, Franklin Lakes, NJ, USA) with Diva software (BD Bio-
sciences, San Jose, CA, USA). Monoclonal antibody panel included
pan B cell marker PE Cy7-conjugated anti-CD19 (BD Biosciences),
memory B cell marker Qdot 655-conjugated anti-CD27 (Invitro-
gen, Carlsbad, CA, USA), and surface IgM with APC-conjugated
anti-IgM (BD Biosciences). B cell percentages ranged from 6.6 to
16.1% of peripheral blood mononuclear cells (PBMC) across the
groups, CD19+ IgM B cells ranged from 70 to 90% of total B cells
(Table 1).
GENERATION OF IGHM CDRH3 AMPLICON LIBRARIES
Analysis of the IGHM CDRH3 transcriptome was performed
using total peripheral blood mRNA without isolation of IgM
B cells. Specificity for the IgM transcriptome was achieved by
reverse amplification primers Cµ15, Cµ5, and Cµ2 homologous
to the IgM constant region (44) (Figure 1A). An amplicon library
was constructed for each subject by RT-PCR using SuperScript™
One-Step RT-PCR with Platinum Taq (Invitrogen) and GoTaq col-
orless Master Mix (Promega, Madison, WI, USA) from ∼200 ng
Table 1 | Demographic characterization of study cohort.
Study
group
Sex Age
(year)
Length of
infection
(year)
ART
length
(year)
CD4 % Viral loada Length
of viral
suppression
(year)
B cell
count
(cells/µl)
CD27− IgM
B cells (%)
CD27+ IgM
B cells (%)
M F Median (25–75% quartile range)
HC 2 2 22 (18–22) N/A N/A N/A N/A N/A 49 (37–112) 68 (52–83) 33 (17–48)
SLE 1 3 15 (14–20) N/A N/A N/A N/A N/A 72 (18–165) 78 (75–85) 22 (15–25)
HIV 1 3 22 (17–24) 0.8 (0.5–2.5) Naive 34 (26–53) 4.0 (2.5–4.9) N/A 254 (124–308) 56 (52–81) 44 (19–48)
HIVTx 1 3 20 (15–25) 16.0 (12.3–21.3) 8.0 (1.5–17.5) 29 (24–31) 1.7 (1.7–1.7) 1.9 (0.5–6.0) 93 (57–440) 63 (60–71) 37 (29–40)
aLog10 HIV-1 RNA copies/ml plasma; N/A, not applicable.
HC, healthy control group; SLE, subjects with systemic lupus erythematosus; HIV, therapy-naïve HIV-infected subjects; HIVTx, HIV-infected individuals with antiretroviral
treatment.
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mRNA (equivalent to about 100,000 B cells or 80,000 IgM B cells)
extracted from total PBMC by MicroPoly[A]Purist™ kit (Ambion,
Austin, TX, USA).
Forward inner primer pan VH-FR3 is located in framework
3 and does not overlap CDRH3 (44). Using the software Oligo
FIGURE 1 | Amplicon libraries and bioinformatic pipeline. (A) Library
construction. IgM specificity was determined by reverse primers
sequences specific for IgM constant region without IgM B cell purification.
(B) Bioinformatic pipeline. Quality sequences (blue box) were analyzed by
querying: (1) customized IGH V-D-J recombination reference sequence
database, (2) IMGT/Junction Analysis, (3) ESPRIT (yellow boxes) to
generate three reports (pink boxes).
(Molecular Biology Insights, Inc., Cascade, CO, USA), pan VH-
FR3 primer was predicted to bind with similar capacity to a
unique sequence in each IGHV family when evaluated against
IGHV family specific reference sequences. In contrast, the pan VH-
FR1 primer (44) displayed different binding capacity to different
IGHV families. Specifically, pan VH-FR1 primer bound prefer-
entially to IGHV3; displayed low binding capacity with IGHV4,
IGHV5, and IGHV7; failed to bind to IGHV2 or IGHV6; and
bound to false priming sites in IGHV1, IGHV4, and IGHV5.
To overcome the different binding capacity of the published
primer sequence, we designed a modified panVH-FR1∗ primer
(CAGGTGCAGCTGGAGCAGTCTGG_) that was one nucleotide
shorter and substituted A and C for T and G in the pub-
lished primer sequence, respectively. When evaluated by Oligo, the
modified panVH-FR1∗ primer displayed similar binding capacity
to each IGHV family reference sequence and no binding to
false priming sites. Forward and reverse primers, pan VH-FR3,
and Cµ2, in the final amplification were conjugated at 5′ ends
with A (GCCTCCCTCGCGCCATCAG) or B (GCCTTGCCAGC-
CCGCTCAG) adaptor, respectively, to generate amplicons ranging
from 150 to 200 nucleotides. Gel-purified amplicons were sub-
mitted to the Interdisciplinary Center for Biotechnology Research
(University of Florida) for 454-pyrosequencing using a Genome
Sequencer FLX (454 Life Sciences) according to the manufacturer’s
protocol.
BIOINFORMATICS PIPELINE
A bioinformatics pipeline was developed to facilitate analysis of
large numbers of relatively short IGHM CDRH3 sequences that
could not be processed by conventional IMGT/V-QUEST analysis
(Figure 1B) (45). Raw reads ranged from 4,500 to 21,000 pyrose-
quences per subject. A quality control step filtered 9–21% low
quality reads with ambiguous nucleotides, more than one error
in either primer tag, or failure to align to reference sequences
in the germ line IGH V-D-J recombination amino acid refer-
ence sequence database (see below), leaving 4,000–17,000 quality
sequences per sample with no significant difference in number of
sequences among the groups (Table 2).
To overcome the limitation of IMGT/V-QUEST for high
throughput classification of relatively short sequences, a novel cus-
tom reference sequence database containing over 700,000 germ
Table 2 | Sequence profiles.
Group Raw
sequences
Removal (%) Quality
sequences
Sequences with
1 nucleotide
substitution (%)
Final quality
sequences
Mean±SD
HC 15,005±2,514 19.9±4.3 11,951±1,490 12.5±0.9 10,460±1,351
SLE 9,613±3,102 16.0±4.7 8,171±2,936 16.3±2.1 6,822±2,411
HIV 7,727±2,236 17.0±5.4 6,341±1,573 13.4±0.9 5,482±1,326
HIVTx 14,746±7,101 18.0±4.4 12,140±5,797 14.8±1.3 10,388±5,034
HC, healthy control group; SLE, subjects with systemic lupus erythematosus; HIV, therapy-naïve HIV-infected subjects; HIVTx, HIV-infected individuals with
antiretroviral treatment.
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line IGH V-D-J amino acid (aa) sequences was established by
generating in silico all possible combinations of germ line IGHV
(285 unique aa sequences), IGHD [44 unique nucleotide sequences
translated in 6 reading frames (RF) producing 222 aa sequences],
and IGHJ (13 unique aa sequences) alleles downloaded from
IMGT (45). Each reference sequence was annotated for IGHV,
IGHD, and IGHJ allele use, IGHD RF in the header with C104
and W118, the 5′ and 3′ boarders of CDRH3, marked by align-
ing to germline IGHV and germline IGHJ reference sequences
using FASTA (http://fasta.bioch.virginia.edu/fasta_www2/fasta_
down.shtml) (46). After removing adapter sequences, query
sequences were then aligned to the reference sequences using
FASTY. Use of IGHV, IGHD, and IGHJ alleles, and IGHD RF of
each query 454-sequence was extrapolated from the header of the
best-matched reference sequence, the C104 and W118 positions
of each query sequence were identified, the part of the query
sequence matched to the C104-W118 region of the reference
sequence was extracted from the entire sequence, and CDRH3
charge and hydropathy index calculated using an in-house code
(47, 48). IMGT/Junction Analysis was then performed allowing
3D-GENEs (49). Using this strategy, the frequency distribution of
IGHD and IGHJ alleles, with IGHD2, IGHD3 and IGHD6, and
IGHJ4 as the dominant genes, was similar to previous reports
(50, 51). However, due to the relatively short IGHV sequence,
we observed some ambiguity in IGHV4 allele assignment; conse-
quently, no comparisons of IGHV alleles without or with SHM
were made.
The total number of mutations including silent- and non-
silent-mutations in CDRH3 between C104 and W118 (40) was
calculated to summarize extent of SHM as: (ΣSHM within
CDRH3 in each SHM+ sequence÷ΣCDRH3 nucleotide length
in each SHM+ sequence)× 100 nucleotides. The effect of N and
P nucleotides to the SHM was similar among the study groups
because the number of N and P nucleotides was minimized when
the setting for D-GENES was 3, and the frequency of sequences
with one D, D-D fusion and D-D-D fusion was similar among
study groups (data not shown).
To avoid potential ambiguity in scoring SHM, an average of
14.3± 0.6% of reads among groups with a single nucleotide differ-
ence from aligned reference sequences was removed from analysis
(Table 2) (40). IGHM sequences with two or more mutations
in CDRH3 were classified as SHM+ representing IgM memory
B cells, while SHM− sequences represent naïve B cells. After
correction of deletion and insertion, the PCR and pyrosequencing-
induced rate of misincorporation tested in our control analysis of
clones of sequences was 0.18 errors per 200 nucleotides, the longest
sequence length, similar to other reports (52–54) and well below
the level of SHM identified in the IgM populations.
ESPRIT was applied to study the biodiversity (genetic com-
plexity) of nucleotide sequences as well as V-D-J combinations
of the IGHM CDRH3 transcriptome repertoire by clustering
the sequences at 0% genetic distance (55). Rarefaction analysis
measures increase in biodiversity along the depth of sequencing
(number of sequences). The deeper the initial slope is, the higher
the biodiversity. Left shift or right shift of the curve indicates an
increase or decrease of biodiversity. Chao1 analysis inferred maxi-
mum biodiversity within the input templates (55, 56). Biodiversity
is influenced by input cell number, the coverage (sequence num-
ber/input cell number), and clonality (frequency of clusters with
more than 10 repeated sequences). Coverage was ∼10% in each
individual to minimize the influence of preferential amplification
of replicate templates. Biodiversity was weighted by the absolute
number of input IgM B cells (calculated from the absolute lym-
phocyte count multiplied by the percentage of CD19+ IgM B cells)
to make the data comparable among study groups. To avoid a
potential bias from sequence number, clonality was averaged on
the same number of sequences randomly drawn 1,000 times from
each sequence pool.
To rule out an influence by differences in sequence numbers
among individuals, a bootstrap resampling method was used to
generate 1,000 rarefaction curves and Chao1 values from random
data sets with the same number of sequences for each individ-
ual. Calculated and estimated biodiversity derived from averages
of 1,000 rarefaction curves produced similar findings (result not
shown).
STATISTICAL ANALYSIS
Comparisons among study groups were performed by ANOVA.
Kolmogorov–Smirnov test was used to test Gaussian distribution.
Overall difference of distribution of CDRH3 length frequencies,
and charge and hydropathy along CDRH3 lengths among study
groups were evaluated as described (57). Comparison of frequency
of sequences in each gene allele, or each CDRH3 length between
SHM+ and SHM− sequences was performed by paired t -test. Pear-
son correlation evaluated the relationship between frequency of
SHM+ sequences and frequency of peripheral CD27+ IgM B cells.
A primary purpose of this pilot study with relatively small sam-
ple size was to detect meaningful trends, thus parametric methods
instead of conservative non-parametric methods were performed.
FIGURE 2 | Frequency of SHM+ IgM sequences exceeds the frequency
of CD27+ IgM B cells in peripheral blood. Frequency of SHM+ IgM
sequences in HIV and HIVTx (treated) groups was similar to HC (healthy
controls), but significantly reduced in individuals with SLE (systemic lupus
erythematosus) (p=0.02). Frequency of SHM+ IgM sequences was
significantly greater than the proportion of CD27+ IgM B cells in each group
(HC, **p=0.001; SLE, ***p<0.0001; HIV, *p=0.004; HIVTx,
***p<0.0001). Reduced frequency of CD27+ IgM B cells in SLE
individuals compared to HC failed to reach statistical significance.
Frequency of SHM+ sequence did not correlate with percent of CD27+ IgM
B cells (r 2 =0.06, p=0.35). Symbols: square, IGHM CDRH3 sequences
with SHM; circle, CD27+ IgM B cells.
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P values were unadjusted for multiple tests to increase sensitivity
to identify differences. Statistical analyses were performed using
SAS version 9.1 (SAS Institute, Cary, NC, USA) with p< 0.05 (two
sided) defined as significant.
RESULTS
SOMATIC HYPERMUTATIONS
IGHM CDRH3 sequences were initially classified by absence or
presence of SHM as a molecular means to distinguish naïve B cells
from IgM memory B cells. Frequency of sequences with SHM in
HIV or HIVTx groups was similar to HC group, but significantly
reduced in individuals with SLE (p= 0.02) (Figure 2). In contrast,
extent of SHM (mutations/100 nucleotides) in IGHM CDRH3
among groups was similar. While the proportion of B cells express-
ing CD27+ IgM memory phenotype was similar among groups,
percentage of phenotypically mature CD27+ IgM B cells was sig-
nificantly less than the frequency of IgM sequences with SHM
within each group (Figure 2). No correlation occurred between
the proportion of CD27+ B cells and SHM (r2= 0.06, p= 0.35).
Subsequent analysis of the IgM transcriptome was based on mol-
ecular assessments of sequences without or with SHM in IGHM
CDRH3.
BIODIVERSITY OF IGHM CDRH3 TRANSCRIPTOME REPERTOIRE IN
HEALTH AND DISEASE
Deep sequencing data sets support application of novel rarefaction
analysis to Ig biodiversity that cannot be inferred from analysis
of limited numbers of sequences. Rarefaction curves provide
comparison of biodiversity along with the depth of sequencing
among study groups; deeper slopes indicate greater biodiver-
sity. IGHM CDRH3 among healthy young adults displayed a
range of biodiversity that overall was greater than biodiversity
in SLE or HIV-1 infection (Figures 3A,B). Differences in biodi-
versity between health and disease were apparent in populations
of IgM sequences without SHM, and to a greater extent among
sequences with SHM due to contribution of SHM. At the depth
of sequencing, none of the rarefaction curves reached satura-
tion, indicating a preponderance of unique sequences and an
FIGURE 3 | Greater biodiversity among populations of IGHM CDRH3
sequences in health control group than in groups with SLE or HIV-1
infection in sequences without or with SHM. Biodiversity in IGHM
CDRH3 sequences without (A) or with (B) SHM in young adults with SLE
(blue lines) and among HIV-infected individuals (red lines, untreated; green
lines, treated) in comparison to healthy counterparts (black lines). Maximum
IGHM CDRH3 biodiversity in input IgM B cells without (C) or with (D) was
significantly lower in SLE (SHM−, p=0.031; SHM+, p=0.021), HIV (SHM−,
p=0.006; SHM+, p=0.004), and HIVTx (SHM−, p=0.020; SHM+,
p=0.010) in comparison with HC. ART failed to normalize IGHM CDRH3
biodiversity in SHM− or SHM+ IGHV CDRH3 repertoire in HIV-infected
subjects (HIVTx vs. HIV, p>0.05).
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extent of IGHM CDRH3 diversity that exceeded the depth of
sequencing.
When maximum IGHM CDRH3 biodiversity was inferred, the
SHM-negative repertoire within healthy individuals displayed sig-
nificantly greater maximum biodiversity than SLE (p= 0.031),
HIV (p= 0.006), or HIVTx (p= 0.020) (Figure 3C). Likewise,
the repertoire with SHM among healthy individuals also dis-
played significantly greater biodiversity than SLE (p= 0.021), HIV
(p= 0.004), or HIVTx (p= 0.010) (Figure 3D). ART failed to nor-
malize biodiversity in IGHM CDRH3 repertoire either without or
with SHM in HIV-infected subjects (Figures 3C,D).
Multiple factors contribute to biodiversity. SHM is one factor,
but extent of SHM was similar among study groups. Likewise,
extent and distribution of clonality were similar among sequences
without or with SHM in each study group with a frequency of
∼99% for unique clusters about 0.2% of clusters with more than
10 repeated sequences. Consequently, to identify molecular dif-
ferences that might contribute to reduced biodiversity without or
with SHM among SLE or HIV-infected groups, CDRH3 length
variation, charge, and hydropathy distribution, as well as IGHD
and IGHJ allelic use, and diversity of allele combinations were
investigated.
CDRH3 LENGTH VARIATION
In all groups, CDRH3 length variation displayed Gaussian distri-
butions (Figure 4). CDRH3 regions without SHM ranged from
4 to 31 amino acid residues with a peak frequency of 15 amino
acids (Figure 4A). SHM+ CDRH3 regions ranged from 5 to
34 amino acids, with lengths of 14 amino acids occurring most
frequently (Figure 4B). Overall length distribution differed sig-
nificantly between sequences without or with SHM (p= 0.004)
(Figure 4C). In general, CDRH3 lengths of 10–17 amino acids
occurred with greater frequency among sequences with SHM
than in sequences without SHM (p< 0.0001). The frequency of
long CDRH3 regions (27–34 amino acids) ranged from 0.03 (±
0.06%) to 0.13% (± 0.12%) in sequences without SHM and 0.13
(± 0.04%) to 0.16% (± 0.10%) in sequences with SHM with
no significant differences among study groups (Figure 5). Charge
and hydropathy distribution across CDRH3 amino acid length
range were similar among all groups indicating that junctional
modifications in sequences without or with SHM were unchanged
(Figure 6).
ALLELIC FREQUENCY OF IGHD AND IGHJ GENES
Nearly 90% of the 44 IGHD alleles were detected across the study
groups (Figures 7A,B). Sequences with SHM showed significant
increases in use of multiple IGHD alleles compared with sequences
lacking SHM. Similarly, over 75% of 13 IGHJ alleles, predomi-
nantly in IGHJ3 and IGHJ4 families, were identified independent
of SHM (Figures 7C,D). A significant increase in three IGHJ alle-
les was detected in sequences with SHM (Figure 7D). While all
study groups had similar IGHD and IGHJ allele usage, the major
difference in allele usage was between sequences with or without
SHM.
BIODIVERSITY OF ALLELE COMBINATIONS
Biodiversity resulting from different combinations of alleles com-
prising the IGHM CDRH3 regions was assessed in health and
FIGURE 4 | Frequency distribution of IGHM CDRH3 amino acid lengths
differed between IgM B cells without or with SHM. (A) Lengths of
SHM− CDRH3 regions displayed a Gaussian distribution ranging from 4 to
31 amino acid residues; lengths of 15 amino acids occurred most
frequently. (B) Lengths of SHM+ CDRH3 regions showed Gaussian
distribution ranging from 5 to 34 amino acids with lengths of 14 amino
acids used most often. (C) Overall length distribution between SHM− and
SHM+ sequences differed [*p=0.004]. Among SHM+ sequences, shorter
lengths [4–9 amino acids] and longer lengths [18–25 amino acids] were
expressed significantly less [↓, p<0.0001], while lengths of 10–17 amino
acids were used more frequently in comparison to SHM− sequences [↑,
p<0.0001]. Bars: HC, black; SLE, blue; HIV-infected individuals: red,
untreated; green, treated. Circles: SHM−, open black; SHM+, open red.
disease groups. Every sequence was composed of V-D-J gene seg-
ments suggesting intact recombination machinery in all individ-
uals independent of health or disease. When comparing numbers
of different combinations along the depth of sequencing using
rarefaction curves, a left shift was observed in healthy individuals,
indicating greater diversification of combinations whether or not
sequences contained SHM (Figures 8A,B). The difference between
health and disease was more pronounced when maximum biodi-
versity was inferred by Chao1 algorithm based on both the richness
and evenness of different V-D-J combinations (Figures 8C,D).
ART failed to restore biodiversity in either group of IgM tran-
scripts. Overall, reduced diversity of V-D-J combinations was a
major contributor to the difference in biodiversity within IGHM
CDRH3 sequences between groups.
IgM SEQUENCES RESEMBLING bn-HIV-Abs
Combinations of alleles within IgM sequences that might be simi-
lar to IgG bn-HIV-Abs were evaluated, but undetected among any
individuals (Table 3) (23, 26, 27, 58–68). In contrast, combinations
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FIGURE 5 | Similar frequency of sequences with CDRH3 lengths longer
than 26 amino acids among study groups. (A) Among SHM− sequences,
frequency of sequences with greater than 26 amino acids CDR3 length
ranged from 0.03 [± 0.06%] to 0.13% [± 0.12%], which was similar among
the four study groups. (B). Among SHM+ sequences, frequency of
sequences with greater than 26 amino acids CDR3 length ranged from 0.13
[± 0.04%] to 0.16% [± 0.10%], which was similar among the four study
groups.
FIGURE 6 | Similar distribution of charge and hydropathy across IGHM CDRH3 length among study groups. Distribution of charge and hydropathy across
IGHM CDRH3 amino acid length range were similar among the four study groups in sequences without [charge, (A); hydropathy index, (C)] or with SHM
[charge, (B); hydropathy index, (D)].
of families found in many bn-HIV-Abs were identified among IgM
sequences across the four study groups (Table 4). While few, if any,
family combinations similar to M66.6/MPER or CD4 binding site
antibodies b12 and VRC-PG04 were detected, combinations simi-
lar to other bn-HIV-Abs were identified among IgM sequences in
a majority of subjects. In general, family combinations were more
frequently represented among IgM sequences with SHM, although
frequencies greater than 0.2% appeared in sequences with or with-
out SHM. Frequency of family combinations was not a function
of the targets in Envelope, as combinations directed toward CD4
binding site, N-linked glycans, V2/V3, or MPER were detected in
almost all individuals.
DISCUSSION
Little is known about how B cell abnormalities in HIV infection
or SLE impact IGH repertoire at the molecular level (1–5, 69–
72). Applying deep sequencing to IgM transcriptomes in total B
cell populations is a strategy to follow development of the IgM
repertoire as a novel molecular assessment at multiple points along
the B cell differentiation pathway, which is highly sensitive for
detecting perturbations within the repertoire in health and dis-
ease. Evaluation of CDRH3 regions in IgM focuses assessment on
transition of the repertoire from initial V-D-J recombination in the
bone marrow, through antigen-induced clonal expansion, SHM,
and establishment of IgM memory B cells (73, 74).
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FIGURE 7 | IGHM IGHD and IGHJ alleles were expressed similarly among
study groups but differently between SHM− and SHM+ IgM B cells.
Number and frequency of IGHD and IGHJ alleles were similar among the four
study groups in IGHM CDRH3 sequences without [IGHD, (A); IGHJ, (C)] or
with SHM [IGHD, (B); IGHJ, (D)]. A significant difference in usage of 11 IGHD
alleles, including IGHD1-1*01, IGHD2-8*01, IGHD2-21*01, IGHD2-21*02,
IGHD3-3*02, IGHD3-16*01, IGHD3-16*02, IGHD4-23*01,
IGHD4/OR15-4a*01, IGHD5-12*01, and IGHD5/OR15-5a*01 (red arrows), and
3 IGHJ alleles, including IGHJ3*01, IGHJ5*01, and IGHJ6*04 (squared by
red), was observed across the groups in SHM+ sequences in comparison to
SHM− sequences (p<0.001 respectively). Bars (mean/SD): HC, black; SLE,
blue; HIV-infected individuals: untreated, red; treated, green.
A memory of antigen is imprinted irreversibly by SHM in
Ig variable region genes, which renders SHM the most accurate
marker to distinguished memory from naïve B cells than B cell
phenotype defined by surface expression of IgM, IgD, and CD27.
While memory CD27+ IgM B cells undergo robust SHM in germi-
nal centers, CD27 is not an immutable indicator of B cell memory
(74–77). We observed IGHM sequences with SHM in CDRH3, in
accordance with observations suggesting an IgM-expressing mem-
ory B cell compartment in the marginal zone (52, 54, 78, 79). The
high percentage of IGHM sequences with SHM may be due to a
larger IgM memory B cell compartment than previously thought,
as well as to increased mRNA levels in IgM B cells with SHM (54),
It is unlikely that plasma cell sequences contributed to the results as
plasma cell frequency in peripheral blood is minimal (80, 81) and
our study design included subjects with no recent immunizations
and/or acute infections to minimize the proportion of plasmacy-
toid B cells undergoing clonal expansion that may skew the IgM
sequence repertoire (82).
A small but significant difference was detected between the
frequency of SHM+ IgM B cells among subjects with SLE, but
not HIV-1 infection, compared to healthy individuals (5, 83, 84).
These cells resemble recirculating marginal zone memory B cells
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FIGURE 8 | Significant decrease in biodiversity resulting from V-D-J allele
recombination in young adults with SLE and HIV-1 infection in
comparison to healthy controls. As assessed by rarefaction, biodiversity of
V-D-J allele recombination along sequence depths decreased in young adults
with SLE (blue lines) and untreated HIV-infected individuals (red lines) in
comparison to their healthy counterparts (black lines) in IgM B cells without
(A) or with SHM (B). Control of viral replication by ART failed to restore
biodiversity in either cell type [green lines in (A,B)]. The maximum biodiversity
of V-D-J allele recombination estimated by Chao1 was significantly greater in
HC subjects than in individuals with SLE and HIV infection in input IgM B cells
without (C) or with SHM (D) (SLE, p=0.016 or 0.041; HIV, p=0.004 for
SHM+ or SHM+; HIVTx, p=0.006 or 0.01, respectively).
that contain somatic mutations and can create considerable IGH
diversity during early childhood in the absence of specific antigenic
stimulation (74, 85).
Rarefaction/Chao1 analysis provides the capacity to com-
pare IGHM biodiversity between sequences expressed by
naïve/transitional B cells and IgM memory B cells defined by
SHM in peripheral blood B cell populations. Within individu-
als, CDRH3 sequence biodiversity resulting from V-D-J recom-
bination generated in the bone marrow was significantly limited
relative to sequence biodiversity following antigen activation and
development of SHM, consistent with estimates of the frequency
of SHM within the B cell repertoire (54). A critical finding is that
biodiversity of the IgM repertoire in the absence or presence of
SHM distinguishes between health and disease. Study groups were
similar ages, an important aspect of the design, as age profoundly
impacts IGH diversity, particularly with respect to the extent of
SHM (86). Overall, IGH affinity maturation is more accurately
assessed by direct molecular analysis through pyrosequencing
of the IgM transcriptome than by phenotypic analysis of B cell
subsets.
While effective treatment restores many HIV-induced B cell
defects, overall B cell function remains impaired (8, 72, 87–89).
Control of HIV replication by cART failed to restore IgM sequence
diversity, although longitudinal studies are needed to evaluate
directly the effects of cART on the B cell repertoire. Abnormal-
ities of IgM B cell populations in HIV-1 infection may persist
as the result of chronic inflammation that continues to impair
B cell populations even when viral replication is optimally con-
trolled (90). Furthermore, persistent low-level viral replication
in the secondary lymphoid tissues where B cells and CD4 T-
cells co-localize may induce lymphoid apoptosis and/or clonal
expansion, contracting the IgM repertoire within memory B cells
(4, 91).
We observed an overall shift of distribution of CDRH3 lengths
toward shorter lengths in sequences with SHM, but no shifts in
hydropathy or charge distribution across the CDRH3 lengths,
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Table 3 | Characteristics of IGHG in bn-HIV-Abs.
Binding
target
bn-HIV-Ab IGHG
IGHV IGHD IGHJ SHM (%) CDRH3 length (aa)
V2, V3 PG16 3-33*05 3-03*01 6*03 20.5 28
PG9 3-33*05 3-03*01 6*03 16.7 28
CH01-CH04 3-20*01 3-10*01 2*01 ∼14.3 24
V3 loop 447-52D 3-15*07 3-10*01 6*03 NA 20
Glycans 2G12 3-21* 5-12* 3* 31.7 16
CD4 bs VRC01 1-02*02 3-16*01 1*01 32.0 14
VRC02 1-02*02 3-16*01 1*01 32.0 14
VRC03 1-02*02 3-* 1*01 30.0 16
VRC-PG04, 04b 1-02*02 5-12*01 2*01 30.0 16
VRC-CH30-34 1-02*02 3-16*01 4*02 ∼25.0 15
b12 1-03*01 3-10*02 6*03 13.0 20
gp41 MPER 2F5 2-05* 3-03* 6* 15.2 22
4E10 1-69* 3-16*/6-19* 1*01 15.6 18
M66.6 5-51*01 3-10*01 6*02 9.3 21
NA, not available.
Table 4 | IGHV, IGHD, and IGHJ combinations similar to known bn-HIV-Ab in IgM repertoire in peripheral blood.
bn-HIV-Ab Target IGHG Frequency of sequences (%)
IGHV IGHD IGHJ Without SHM With SHM
HC SLE HIV HIVTx HC SLE HIV HIVTx
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
VRC-CH30-34 CD4 bs 1* 3* 4*
2G12 Glycans 3* 5* 3*
CH01-CH04 V2, V3 3* 3* 2*
4E10 MPER 1* 3*/6*a 1*
VRC01, 02, 03 CD4 bs 1* 3* 1*
2F5 MPER 2* 3* 6*
PG16,
9/447-52D
V2, V3/V3
loop
3* 3* 6*
VRC-PG04,
04b
CD4 bs 1* 5* 2*
b12 CD4 bs 1* 3* 6*
M66.6 MPER 5* 3* 6*
aSequences in 4E10 align to IGHD3 or IGHD6 with a similar number of nucleotides.
White or gray=<0.01% of sequences; yellow=0.01–0.1% of sequences; orange=>0.1–0.5% of sequences; rust=>0.5% of sequences.
as found in assessments using sorted IgM memory B cells (51,
92). Differences may reflect a distinct developmental program
for CD27+ IgM marginal zone B cells that develop outside typ-
ical T-dependent or T-independent pathways (85). Overall, nei-
ther HIV-1 infection nor SLE produces profound alterations in
allele usage, CDRH3 length, hydropathy, or charge distribution
within the IgM repertoire, indicating that intrinsic mechanisms
for generating junctional diversity and SHM are functional.
Decreased biodiversity in IGHM CDRH3 sequences without
SHM supports the observation that HIV-1 reduces the breadth
of the IgM repertoire early in B cell development (93, 94). In
contrast, reduced biodiversity within the SHM+ IGHM reper-
toire of HIV-infected or SLE subjects might reflect polyclonal
expansion, reduced B cell precursors, and/or B cell exhaustion.
While pyrosequencing provides an unprecedented view of the
human IgM B cell repertoire, depth of sampling of periph-
eral blood B cell populations was insufficient to detect directly
expanded B cell clones, which may be expected from polyclonal
expansion. In a study of healthy individuals the estimated IGH
pool was greater than 1,000,000 different rearrangements so that
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even with deep sequencing no single sequence would be repre-
sented multiple times (39). Polyclonal expansion of limited num-
ber of clones would decrease overall diversity without impacting
junctional modification, SHM generation, CDRH3 length distri-
bution, or biochemical characteristics of amino acid residues.
The healthy subjects enrolled in our study had no recent ill-
nesses or immunizations that might skew their repertoire (86).
In contrast, both the SLE and untreated HIV-infected subjects
had active disease, yet CDRH3 length diversity and gene usage
was not impacted. Decreased B cell numbers in the peripheral
blood are restored by control of viral replication but therapy
failed to restore sequence biodiversity in either SHM+ or SHM−
populations (88, 89). This assessment of the IGHM sequence
repertoire provides a basis for examining late stage B cell devel-
opment through pyrosequencing of IGH in IgG and IgA reper-
toires within the same mRNA used for the IgM transcriptome,
which will expand molecular understanding of the biodiver-
sity of the peripheral blood B cell repertoire in health and
disease.
Autoantibodies can result from defective early B cell tolerance
in the bone marrow or arise as naïve B cells encounter antigen,
undergo SHM and affinity maturation (6). Our study identified
no skewing with the IGHM repertoire based on assessment of
CDRH3 length,charge,and hydropathy within sequences that con-
tained or lacked SHM, which is not surprising as assessment of the
B cell repertoire using clonal sequencing of V-D-J recombination
in SLE subjects also failed to reveal major abnormalities (6, 95).
Overall, results provide a framework for in-depth studies of the
molecular mechanisms that lead to lower biodiversity in SLE and
HIV-infected individuals.
An intense area of study in the development of an effective
HIV-1 vaccine is the capacity of the repertoire to generate bn-
HIV-Abs. Most characterized bn-HIV-Abs are IgG isotype with
extensive affinity maturation and SHM (58, 61, 62, 66, 67, 95). IgA
autoantibodies, including anti-CCR5 or anti-gp41, produced by
a subset of the HIV-1-exposed seronegative individuals or long-
term non-progressors, contribute to effective prevention of viral
entry at major mucosal portals (29, 32, 96–98). Both IgG and
IgA are derived from IgM. Our assessment of the IgM repertoire
revealed in all subjects low frequency B cells with the same combi-
nations of IGHV, IGHD, and IGHJ gene families found in known
IgG bn-HIV-Abs, particularly those which bind to CD4 binding
site, gp41 MPER, V2/V3, glycans in C2, C3, V4 and C4, and V3
loop (23, 26, 27, 58, 60–67, 99, 100). Clearly the IgM repertoire
across individuals normally includes B cells with the potential
to express IgG bn-HIV-Abs, holding promise that these antibod-
ies can be induced as part of an overall HIV vaccine strategy.
Biochemical characteristics of IgM antibody sequences provide
an assessment of functional potential of IgM antibodies. In our
study, significant differences in frequency distribution of CDRH3
lengths, or distribution of charge or hydropathy along CDRH3
lengths in IgM repertoire of SLE or HIV-infected individuals were
found in comparisons with HC. Results suggest that IgM antibod-
ies with characteristics of IgG bn-HIV-Ab were not produced at
levels sufficient to perturb IgM repertoire in SLE or HIV-infected
individuals.
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